Augmentin®
Amoxicillin / Clavulanate · oral tablet
Antibiotic
Approved uses
Infections due to beta-lactamase producing isolates: lower respiratory tract, acute bacterial otitis media, sinusitis, skin and skin structure, urinary tract
Adults and pediatric patients 40 kg or more: 500 mg/125 mg every 12 hours or 250 mg/125 mg every 8 hours, or 875 mg/125 mg every 12 hours or 500 mg/125 mg every 8 hours for more severe and respiratory infection. Pediatric patients 12 weeks and older, on the amoxicillin component up to the adult dose: 45 mg/kg/day divided every 12 hours or 40 mg/kg/day divided every 8 hours for otitis media, sinusitis, lower respiratory tract and more severe infections, or 25 mg/kg/day divided every 12 hours or 20 mg/kg/day divided every 8 hours for less severe infection. Neonates and infants under 12 weeks: 30 mg/kg/day divided every 12 hours.
OFF-LABELNot in the FDA label for this product
Acute dacryocystitis
Label regimen for more severe infection: adults and patients over 40 kg 875 mg/125 mg every 12 hours or 500 mg/125 mg every 8 hours; pediatric patients 12 weeks and older 45 mg/kg/day of the amoxicillin component divided every 12 hours.
Retrospective · in vitro only
Single-center retrospective chart review of 137 patients with acute or chronic dacryocystitis, 205 samples and 156 isolates: S. aureus was the most common at 46 of 156 (30%), then Pseudomonas species 19 of 156 (12%) and Propionibacterium acnes 15 of 156 (10%). On in vitro susceptibility the two most effective oral antibiotics in this population were levofloxacin and amoxicillin/clavulanate, but the latter would still have met at least one resistant organism in 32% of patients and potentially another 8% (levofloxacin 16% and 15%). The authors conclude that routine treatment with any single antibiotic may fail in up to a third of patients and recommend culturing at the time empiric therapy is started. Susceptibility data only, no clinical outcome and no dosing data.
Preseptal (periorbital) cellulitis
Label regimen for more severe infection: adults and patients over 40 kg 875 mg/125 mg every 12 hours or 500 mg/125 mg every 8 hours; pediatric patients 12 weeks and older 45 mg/kg/day of the amoxicillin component divided every 12 hours.
Narrative review · no trials
A narrative review of pediatric preseptal and orbital cellulitis lists amoxicillin-clavulanate among the antibacterials often used, notes significant variation in agent selection, supports transition from IV to oral therapy once clinical and laboratory improvement is clear, and reports total durations trending toward about 2 weeks. That is expert review, not comparative trial evidence. The nearest treatment data are postseptal, not preseptal: in a retrospective series of 48 children with subperiosteal orbital abscess complicating acute ethmoiditis, oral amoxicillin-clavulanate was the step-down for about 8.5 days after a mean of four days of IV third-generation cephalosporin plus metronidazole, given to 94% of the children, and all were cured without sequelae. The practical argument for this product over plain amoxicillin is spectrum, since the label lists S. aureus, H. influenzae and M. catarrhalis among covered organisms.
Contraindications
- History of a serious hypersensitivity reaction such as anaphylaxis or Stevens-Johnson syndrome to amoxicillin, clavulanate, or other beta-lactams including penicillins and cephalosporins.
- Previous cholestatic jaundice or hepatic dysfunction associated with this combination.
Tablets 250 mg/125 mg, 500 mg/125 mg and 875 mg/125 mg; chewable tablets 125 mg/31.25 mg, 250 mg/62.5 mg, 200 mg/28.5 mg and 400 mg/57 mg; powder for oral suspension 125 mg/31.25 mg and 250 mg/62.5 mg per 5 mL in 75, 100 and 150 mL bottles, 200 mg/28.5 mg and 400 mg/57 mg per 5 mL in 50, 75 and 100 mL bottles
A penicillin-class antibacterial combined with a beta-lactamase inhibitor. Clavulanic acid inactivates some beta-lactamases and has good activity against the clinically important plasmid-mediated beta-lactamases frequently responsible for transferred drug resistance. This protects amoxicillin from degradation by some beta-lactamase enzymes and extends its spectrum to many bacteria normally resistant to amoxicillin. The combination is active against most isolates of S. aureus, Enterobacter species, E. coli, H. influenzae, Klebsiella species and M. catarrhalis.
Warnings & Precautions
- Hypersensitivity reactions: Serious and occasionally fatal anaphylactic reactions have been reported with beta-lactam antibacterials and are more likely with a history of penicillin hypersensitivity or sensitivity to multiple allergens. Before starting, ask about previous hypersensitivity reactions to penicillins, cephalosporins or other allergens; if an allergic reaction occurs, discontinue and institute appropriate therapy.
- Hepatic dysfunction: Hepatitis and cholestatic jaundice have been associated with use; toxicity is usually reversible but deaths have been reported. Discontinue if signs or symptoms of hepatitis occur, and monitor hepatic function at regular intervals in patients with hepatic impairment.
- Clostridium difficile associated diarrhea: CDAD may range from mild diarrhea to fatal colitis, and hypertoxin-producing strains may require colectomy. Consider CDAD in any diarrhea after antibacterial use; take a careful history, since CDAD has been reported over 2 months after. If CDAD is suspected or confirmed, antibacterials not directed against C. difficile may need to be discontinued, with fluid, electrolyte and protein support, C. difficile treatment and surgical evaluation as clinically indicated.
- Skin rash in mononucleosis: A high percentage of patients with mononucleosis who receive amoxicillin develop an erythematous rash; do not administer in mononucleosis.
- Microbial overgrowth: Superinfection with fungal or bacterial pathogens should be considered during therapy; if it occurs, stop treatment and institute appropriate therapy.
- Phenylketonuria: Chewable tablets and oral suspension contain aspartame, 2.1 mg phenylalanine per 200 mg chewable tablet, 4.2 mg per 400 mg chewable tablet, and 7 mg per 5 mL of the 200 mg/5 mL or 400 mg/5 mL suspension; the other formulations contain no phenylalanine. The every 12 hour 200 mg/5 mL and 400 mg/5 mL suspensions and 200 mg and 400 mg chewable tablets should not be used by phenylketonurics.
- Development of drug-resistant bacteria: Prescribing in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit and increases the risk of drug-resistant bacteria.
- Tablet substitution: Two 250 mg tablets are not equivalent to one 500 mg tablet because both strengths contain 125 mg clavulanic acid; the 250 mg tablet and the 250 mg chewable tablet are not interchangeable (125 mg versus 62.5 mg clavulanic acid); the 250 mg tablet should not be used until the child weighs at least 40 kg.
- Increased and prolonged amoxicillin blood concentrations: Probenecid decreases renal tubular secretion of amoxicillin, and coadministration of probenecid is not recommended.
- Increased incidence of rashes: Concurrent allopurinol and amoxicillin increases the incidence of rashes compared with amoxicillin alone.
- Prolonged prothrombin time: Abnormal prolongation of prothrombin time with increased INR has been reported with amoxicillin and oral anticoagulants; monitor when anticoagulants are prescribed concurrently, and anticoagulant dose adjustments may be necessary.
- Reduced contraceptive efficacy: Augmentin may affect intestinal flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.
- False-positive urine glucose tests: High urine concentrations of amoxicillin may cause false-positive reactions with CLINITEST, Benedict's Solution or Fehling's Solution; use glucose tests based on enzymatic glucose oxidase reactions.
Common Side Effects
The most frequent adverse reactions in clinical trials were diarrhea or loose stools (9%), nausea (3%), skin rashes and urticaria (3%), vomiting (1%) and vaginitis (1%); abdominal discomfort, flatulence and headache occurred in under 1%. The overall incidence, and diarrhea in particular, increased with the higher recommended dose, and less than 3% of patients stopped for drug-related reactions. Postmarketing hepatitis and cholestatic jaundice have been reported more commonly in the elderly, in males or with prolonged treatment; they may begin during or several weeks after therapy, may be severe, and are usually reversible, though deaths have been reported. Other reports include pseudomembranous colitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, agranulocytosis, interstitial nephritis and convulsions; most reports of tooth discoloration occurred in pediatric patients.
Pregnancy: Category B. Reproduction studies in pregnant rats and mice at oral doses up to 1200 mg/kg/day of the 2 to 1 amoxicillin to clavulanate formulation showed no evidence of fetal harm, roughly 4 and 2 times the maximum recommended adult human dose by body surface area for the amoxicillin component (875 mg every 12 hours) and 9 and 4 times for clavulanate (125 mg every 8 hours); there are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, use during pregnancy only if clearly needed.
Lactation: Amoxicillin has been shown to be excreted in human milk, and use by a nursing mother may lead to sensitization of the infant; exercise caution.
Safety and effectiveness of the powder for oral suspension and chewable tablets are established in pediatric patients. Amoxicillin elimination may be delayed in neonates and young infants because of incompletely developed renal function, so dosing should be modified under 12 weeks (3 months) of age.